无诱因静脉血栓栓塞症患者出血风险评估工具:PLATO-VTE研究分析
PLATO-VTE前瞻性队列纳入514例≥40岁首次无诱因VTE患者,在诊断时及治疗3个月后计算RIETE、VTE-BLEED、CHAP、VTE-PREDICT和ABC-Bleeding五种出血风险工具的区分度。24个月随访中38例(7.4%)发生临床相关出血,各工具AUROC为0.50至0.58,区分度差;高危组出血发生率0%至13.0%,非高危组7.7%至9.6%,HR为0.93至1.67。作者认为数据不支持在无诱因VTE患者中使用这些工具。
要点
- 五种出血风险工具AUROC仅0.50至0.58,区分度差。
- 高危组比例从RIETE的1.4%到VTE-BLEED的36.9%不等。
- 高危组出血发生率0%至13.0%,非高危组7.7%至9.6%。
核心结论
- 在该队列中,现有出血风险工具的区分度差,数据不支持在无诱因VTE患者中使用这些工具。
研究设计与样本
- PLATO-VTE为前瞻性队列研究,纳入年龄≥40岁、首次无诱因VTE的患者,共514例。
- 在VTE诊断时及治疗3个月后计算RIETE、VTE-BLEED、CHAP、VTE-PREDICT和ABC-Bleeding五种工具的出血风险估计值。
- 主要结局为24个月随访期间按国际血栓与止血学会(ISTH)标准定义的临床相关出血;采用受试者工作特征曲线下面积(AUROC)评估区分度;按预设阈值将患者分为出血高危和非高危,用风险比(HR)比较两组出血风险。
主要发现
- 514例中38例(7.4%)发生治疗期间出血。
- AUROC:ABC-Bleeding为0.58(95%CI 0.48-0.68),RIETE为0.56(95%CI 0.46-0.66),CHAP为0.53(95%CI 0.43-0.64),VTE-BLEED为0.50(95%CI 0.41-0.59),VTE-PREDICT为0.50(95%CI 0.40-0.60)。
- 高危患者比例从RIETE的1.4%到VTE-BLEED的36.9%不等。
- 高危组出血发生率从RIETE的0%到ABC-Bleeding的13.0%不等;非高危组从ABC-Bleeding的7.7%到RIETE的9.6%不等。
- HR从VTE-BLEED的0.93(95%CI 0.46-1.9)到ABC-Bleeding的1.67(95%CI 0.86-3.2)不等。
临床怎么用
- 原文结论认为这些数据不支持在无诱因VTE患者中使用现有出血风险工具。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Guidelines suggest indefinite anticoagulation after unprovoked venous thromboembolism (VTE) unless the bleeding risk is high, yet there is no consistent guidance on assessing bleeding risk. OBJECTIVES: This study aimed to evaluate the performance of 5 bleeding risk tools (RIETE, VTE-BLEED, CHAP, VTE-PREDICT, and ABC-Bleeding). METHODS: PLATO-VTE, a prospective cohort study, included patients aged ≥40 years with a first unprovoked VTE. Risk estimates were calculated at VTE diagnosis and after 3 months of treatment. Primary outcome was clinically relevant bleeding, as per International Society on Thrombosis and Haemostasis criteria, during 24-month follow-up. Discrimination was assessed by the area under the receiver operating characteristic curve (AUROC). Patients were classified as having a "high risk" and "non-high risk" of bleeding according to predefined thresholds; bleeding risk in both groups was compared by hazard ratios (HRs). RESULTS: Of 514 patients, 38 (7.4%) had an on-treatment bleeding. AUROCs were 0.58 (95% CI, 0.48-0.68) for ABC-Bleeding, 0.56 (95% CI, 0.46-0.66) for RIETE, 0.53 (95% CI, 0.43-0.64) for CHAP, 0.50 (95% CI, 0.41-0.59) for VTE-BLEED, and 0.50 (95% CI, 0.40-0.60) for VTE-PREDICT. The proportion of high-risk patients ranged from 1.4% with RIETE to 36.9% with VTE-BLEED. The bleeding incidence in the high-risk groups ranged from 0% with RIETE to 13.0% with ABC-Bleeding, and in the non-high-risk groups, it varied from 7.7% with ABC-Bleeding to 9.6% with RIETE. HRs ranged from 0.93 (95% CI, 0.46-1.9) for VTE-BLEED to 1.67 (95% CI, 0.86-3.2) for ABC-Bleeding. Recalibration at 3-month follow-up did not alter the results. CONCLUSION: In this cohort, discrimination of currently available bleeding risk tools was poor. These data do not support their use in patients with unprovoked VTE.
引用
- Guman NAM, Becking AL, Weijers SS, et al. Risk assessment tools for bleeding in patients with unprovoked venous thromboembolism: an analysis of the PLATO-VTE study. J Thromb Haemost. 2024. PMID: 38866248. doi:10.1016/j.jtha.2024.05.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。